Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.63, while State Street SPDR S&P Biotech ETF trades at $152.07. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $97.74 | $164.28 |
52-Week Low | $91.59 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.625 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF has demonstrated stable dividend distributions with recent payouts around $0.40-0.41 per share. Emerging market bond ETFs face increased institutional interest but remain sensitive to Federal Reserve policy and geopolitical risks.
The outlook for EMB hinges on emerging market sovereign debt performance amid shifting Fed rates and global risk appetite. Key opportunities include attractive yields relative to developed markets, while risks center on currency volatility and sovereign default exposure in hard currency bonds. Current technical weakness suggests cautious near-term positioning.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
